Stephen Christopher Linthwaite
Net Worth
Last updated:
What is Stephen Christopher Linthwaite net worth?
The estimated net worth of Mr. Stephen Christopher Linthwaite is at least $11,339,237 as of 22 Feb 2022. He owns shares worth $539,237 as insider and has received compensation worth at least $10,800,000 in Standard BioTools Inc..
What is the salary of Stephen Christopher Linthwaite?
Mr. Stephen Christopher Linthwaite salary is $1,200,000 per year as Pres, Chief Executive Officer & Director in Standard BioTools Inc..
How old is Stephen Christopher Linthwaite?
Mr. Stephen Christopher Linthwaite is 52 years old, born in 1973.
What stocks does Stephen Christopher Linthwaite currently own?
As insider, Mr. Stephen Christopher Linthwaite owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Standard BioTools Inc. (FLDM) | Pres, Chief Executive Officer & Director | 145,347 | $3.71 | $539,237 |
What does Standard BioTools Inc. do?
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Stephen Christopher Linthwaite insider trading
Standard BioTools Inc.
Mr. Stephen Christopher Linthwaite has made only one insider trade between 2016-2022, according to the Form 4 filled with the SEC.
As of 22 Feb 2022 he still owns at least 145,347 units of FLDM stock.
Standard BioTools key executives
Standard BioTools Inc. executives and other stock owners filed with the SEC:
- Mr. Bradley Allen Kreger (50) Senior Vice President of Global Operations
- Mr. Colin McCracken (52) Chief Commercial Officer
- Mr. Nicholas S. Khadder (51) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Stephen Christopher Linthwaite (52) Pres, Chief Executive Officer & Director
- Mr. Vikram Jog (69) Chief Financial Officer